BackIGM Biosciences Overview

IGM Biosciences Total Revenue

Latest total revenue for IGMS: $150M, below the Healthcare sector average of $110B.

Get informed when a big investor buys or sells

+ Follow

Quarterly Revenue

$143.62M
11353.19% YoY

As of Jun 2025

Annual Revenue (TTM)

$145.05M
4882.82% YoY

Trailing 12 months ending Jun 2025

Average Revenue (Comparison Companies)

Loading

Total Revenue History

Loading

Total Revenue Comparison

Loading

Annual Revenue Growth Rate (%)

Loading

Annual Revenue Growth (Absolute)

Loading

IGM Biosciences (IGMS) FAQ

IGM Biosciences (IGMS) currently reports a total revenue of $150M as of June 2025. That compares with $2.9M in the prior-year period — up 4882.8% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore IGM Biosciences's total revenue history and peer comparisons.

IGM Biosciences's total revenue increased from $2.9M to $150M — a 4882.8% year-over-year increase (period ending June 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

IGM Biosciences's total revenue of $150M is lower than the Healthcare sector average of $110B. That is roughly 99.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

IGM Biosciences reported $150M in total revenue as of June 2025. That compares with $2.9M in the prior-year period — up 4882.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $150M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for IGM Biosciences, and consider following IGMS for alerts when major investors trade the stock.